Matches in Wikidata for { <http://www.wikidata.org/entity/Q106642518> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q106642518 description "clinical trial" @default.
- Q106642518 description "ensayo clínico" @default.
- Q106642518 description "ensayu clínicu" @default.
- Q106642518 description "klinisch onderzoek" @default.
- Q106642518 description "клінічне випробування" @default.
- Q106642518 description "կլինիկական փորձարկում" @default.
- Q106642518 description "临床试验" @default.
- Q106642518 name "To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chem" @default.
- Q106642518 name "To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chem" @default.
- Q106642518 type Item @default.
- Q106642518 label "To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chem" @default.
- Q106642518 label "To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chem" @default.
- Q106642518 prefLabel "To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chem" @default.
- Q106642518 prefLabel "To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chem" @default.
- Q106642518 P1050 Q106642518-68142E68-A4DA-430C-83BB-0E076EB18ADD @default.
- Q106642518 P1132 Q106642518-C23D457D-822A-473A-91B0-9EAA1F99BC26 @default.
- Q106642518 P1476 Q106642518-F6EF52E8-2D59-4794-A521-F33C1E80EFFE @default.
- Q106642518 P1813 Q106642518-857B54E3-CA50-437A-AF24-E67A36AEDBEE @default.
- Q106642518 P2899 Q106642518-00B69D2E-6BC6-44C8-BD80-F1D2FAA56025 @default.
- Q106642518 P3098 Q106642518-5BAC857D-8CF2-4F76-BC1E-A1C7CB6E6B26 @default.
- Q106642518 P31 Q106642518-DB6FB5D5-3FFA-4746-A208-8EDE0B03FF5F @default.
- Q106642518 P4135 Q106642518-B29F1AF8-AEAE-4CC7-BBAE-EDC129CC8563 @default.
- Q106642518 P580 Q106642518-DA3B2448-2D72-4648-8A6A-73974E244CB3 @default.
- Q106642518 P582 Q106642518-1747230B-7997-4B5F-A894-587B3EDE2C85 @default.
- Q106642518 P6099 Q106642518-BD1DA5C4-6DF1-4B17-8DF4-F085729E50C1 @default.
- Q106642518 P8005 Q106642518-9207B17D-6B05-4B68-AD81-81DA33E9DDCF @default.
- Q106642518 P8363 Q106642518-4A7DBE39-F18B-4D84-B6E3-9FBC21F5E4EB @default.
- Q106642518 P1050 Q33525 @default.
- Q106642518 P1132 "+318" @default.
- Q106642518 P1476 "A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, Study to Assess the Efficacy and Safety of Furmonertinib (AST2818) Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy" @default.
- Q106642518 P1813 "FORWARD" @default.
- Q106642518 P2899 "+18" @default.
- Q106642518 P3098 "NCT04853342" @default.
- Q106642518 P31 Q30612 @default.
- Q106642518 P4135 "+75" @default.
- Q106642518 P580 "2021-04-17T00:00:00Z" @default.
- Q106642518 P582 "2023-12-01T00:00:00Z" @default.
- Q106642518 P6099 Q42824827 @default.
- Q106642518 P8005 Q76649614 @default.
- Q106642518 P8363 Q78089383 @default.